AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.

AN2 Therapeutics develops therapies for rare, chronic, and serious infectious diseases using their boron chemistry platform. Self-described as having a pipeline of novel boron-based compounds.

AN2 Therapeutics

AN2 Therapeutics | 1,734 followers on LinkedIn. Developing therapies for rare, chronic, and serious infectious diseases | AN2 Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet needs.  Founded by a team of experienced industry leaders in infectious disease drug research and development and boron chemistry, we have a passion for addressing the challenges of infectious disease and improving global human health.   For more information, please visit www.an2therapeutics.com.

Sanjay Chanda

Executive Director, Clinical Operations

Kevin O'Shea

CEO & Co-Founder at AN2 Therapeutics

Eric Easom

Chief Financial Officer | Board Member

Stephanie Wong

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

AN2 Therapeutics supports the companionship that pets provide. Earlier this week we welcomed Taiko, Hiero, Niall, Blue, Piper, Peanut, Lizzie, and Elroy to our offices in Menlo Park.

Back from #ATS2024 ! We’re excited to have connected with healthcare professionals and clinicians supporting patients with rare, chronic and serious pulmonary diseases. #ATS

April 14 is #WorldChagasDay . We take this important opportunity to draw attention to this neglected disease that affects ~6 to 7 million people globally. We are proud to advance our preclinical drug candidate AN2-502998 (formerly AN15368) as a potential new treatment for patients with #ChagasDisease .

Today is #WorldNTDDay , a day where we raise awareness for the neglected tropical diseases that affect the world’s most vulnerable populations. At AN2 we have a passion for addressing the challenges of infectious diseases and improving global human health. #WorldNTDDay #research #Chagas #neglectedtropicaldiseases

COM:AN2THERAPEUTICS

AN2 Therapeutics

Last Close

1.23

22/11 21:00

Market Cap

77.56M

Beta: -

Volume Today

1.25M

Avg: -

Financials Not Available